[Redo Surgical Aortic Valve Replacement for Dysfunctional Transcatheter Aortic Valve Implanted for Degenerated Surgical Bioprosthesis].

Q4 Medicine
Hiroyuki Morishita, Masahiko Ezure, Yutaka Hasegawa, Yasuyuki Yamada, Joji Hoshino, Shuichi Okada, Yoshifumi Itoda, Kazuki Tamura, Takashi Soda
{"title":"[Redo Surgical Aortic Valve Replacement for Dysfunctional Transcatheter Aortic Valve Implanted for Degenerated Surgical Bioprosthesis].","authors":"Hiroyuki Morishita, Masahiko Ezure, Yutaka Hasegawa, Yasuyuki Yamada, Joji Hoshino, Shuichi Okada, Yoshifumi Itoda, Kazuki Tamura, Takashi Soda","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>An 81-year-old man underwent surgical aortic valve replacement (SAVR) for stenotic bicuspid valve with a 21-mm CEP bioprosthesis 17 years ago. Four years ago, he underwent valve-in-valve (ViV)transcatheter aortic valve replacement (TAVR) using a self-expandable Evolut R 23-mm valve due to structural valve deterioration (SVD) and redo SAVR was indicated because of repeat SVD and heart failure symptoms. Transcatheter valve and prior surgical valve adhered to the anterior mitral leaflet. Removal of the valve caused perforation, which required repair. Aortic valve replacement was performed using an Epic Plus 21-mm valve. SAVR after TAVR is more invasive and has higher mortality than ViV, but in younger or low-risk patients, treatment should be planned with long-term prognosis in mind.</p>","PeriodicalId":17841,"journal":{"name":"Kyobu geka. The Japanese journal of thoracic surgery","volume":"79 4","pages":"254-257"},"PeriodicalIF":0.0000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kyobu geka. The Japanese journal of thoracic surgery","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

An 81-year-old man underwent surgical aortic valve replacement (SAVR) for stenotic bicuspid valve with a 21-mm CEP bioprosthesis 17 years ago. Four years ago, he underwent valve-in-valve (ViV)transcatheter aortic valve replacement (TAVR) using a self-expandable Evolut R 23-mm valve due to structural valve deterioration (SVD) and redo SAVR was indicated because of repeat SVD and heart failure symptoms. Transcatheter valve and prior surgical valve adhered to the anterior mitral leaflet. Removal of the valve caused perforation, which required repair. Aortic valve replacement was performed using an Epic Plus 21-mm valve. SAVR after TAVR is more invasive and has higher mortality than ViV, but in younger or low-risk patients, treatment should be planned with long-term prognosis in mind.

[重做手术主动脉瓣置换术治疗功能障碍经导管主动脉瓣植入变性外科生物假体]。
一例81岁男性患者于17年前用21毫米CEP生物假体行主动脉瓣置换术(SAVR)治疗狭窄的二尖瓣。四年前,由于结构性瓣膜恶化(SVD),他使用自膨胀的Evolut R 23毫米瓣膜进行了经导管瓣内瓣膜置换术(TAVR),由于重复SVD和心力衰竭症状,他进行了重做SAVR。经导管瓣膜和先前的手术瓣膜粘附在前二尖瓣小叶上。移除阀门导致穿孔,需要修复。主动脉瓣置换术采用Epic Plus 21毫米瓣膜。TAVR后SAVR的侵袭性更强,死亡率高于ViV,但在年轻或低危患者中,治疗计划应考虑长期预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
213
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书